Sentiment-Signal
20,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Amylyx Pharmaceuticals, Inc. |
|---|---|
| Ticker | AMLX |
| CIK | 0001658551 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,35 Mrd. USD |
| Beta | -0,21 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -144,735,000 | -1.53 | 332,645,000 | 305,259,000 |
| 2025-09-30 | 10-Q | 0 | -34,386,000 | -0.37 | 362,741,000 | 331,996,000 |
| 2025-06-30 | 10-Q | 0 | -41,443,000 | -0.46 | 194,598,000 | 167,877,000 |
| 2025-03-31 | 10-Q | 0 | -35,907,000 | -0.42 | 219,676,000 | 201,417,000 |
| 2024-12-31 | 10-K | 87,371,000 | -301,743,000 | -4.43 | 193,634,000 | 164,765,000 |
| 2024-09-30 | 10-Q | 416,000 | -72,704,000 | -1.07 | 250,713,000 | 196,203,000 |
| 2024-06-30 | 10-Q | -1,023,000 | -72,700,000 | -1.07 | 332,162,000 | 261,309,000 |
| 2024-03-31 | 10-Q | 88,643,000 | -118,793,000 | -1.75 | 417,457,000 | 324,436,000 |
| 2023-12-31 | 10-K | 380,786,000 | 49,271,000 | 0.70 | 517,454,000 | 433,432,000 |
| 2023-09-30 | 10-Q | 102,693,000 | 20,893,000 | 0.30 | 466,584,000 | 418,400,000 |
| 2023-06-30 | 10-Q | 98,216,000 | 22,074,000 | 0.31 | 453,588,000 | 386,365,000 |
| 2023-03-31 | 10-Q | 71,428,000 | 1,573,000 | 0.02 | 407,958,000 | 352,648,000 |
| 2022-12-31 | 10-K | 22,230,000 | -198,375,000 | -3.39 | 391,453,000 | 340,607,000 |
| 2022-09-30 | 10-Q | 345,000 | -53,756,000 | -0.92 | 181,443,000 | 144,028,000 |
| 2022-06-30 | 10-Q | -54,067,000 | -0.93 | 225,240,000 | 192,789,000 | |
| 2022-03-31 | 10-Q | -47,848,000 | -0.93 | 274,438,000 | 240,946,000 | |
| 2021-12-31 | 10-K | 285,000 | -87,931,000 | -13.35 | 105,614,000 | -151,168,000 |
| 2021-09-30 | 10-Q | 285,000 | -23,142,000 | -3.42 | -124,070,000 | |
| 2021-06-30 | 10-Q | -21,922,000 | -3.41 | -101,893,000 | ||
| 2021-03-31 | 10-Q | -14,523,000 | -80,631,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | FRATES JAMES M | Officer, Chief Financial Officer | Open Market Sale | -7,909 | 14.52 | -114,851.33 | -111,2% | |
| 2026-03-02 | Bedrosian Camille L | Officer, Chief Medical Officer | Open Market Sale | -6,461 | 14.58 | -94,205.26 | -91,2% | |
| 2026-02-02 | FRATES JAMES M | Officer, Chief Financial Officer | Open Market Sale | -3,557 | 14.65 | -52,096.89 | -50,5% | |
| 2026-01-06 | FRATES JAMES M | Officer, Chief Financial Officer | Open Market Sale | -3,326 | 11.11 | -36,953.86 | -35,8% | |
| 2025-12-01 | Bedrosian Camille L | Officer, Chief Medical Officer | Open Market Sale | -6,580 | 14.35 | -94,418.39 | -91,5% | |
| 2025-09-30 | Bedrosian Camille L | Officer, Chief Medical Officer | Open Market Sale | -12,039 | 14.58 | -175,517.78 | -170,0% | |
| 2025-09-30 | FRATES JAMES M | Officer, Chief Financial Officer | Open Market Sale | -10,558 | 14.65 | -154,650.42 | -149,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.